Divergence between the high rate of p53 mutations in skin carcinomas and the low prevalence of anti-p53 antibodies.
Circulating anti-p53 antibodies have been described and used as tumoural markers in patients with various cancers and strongly correlate with the p53 mutated status of the tumours. No study has yet looked at the prevalence of such antibodies in skin carcinoma patients although these tumours have been shown to be frequently p53 mutated. Most skin carcinoma can be diagnosed by examination or biopsy, but aggressive, recurrent and/or non-surgical cases' follow up would be helped by a biological marker of residual disease. We performed a prospective study looking at the prevalence of anti-p53 antibodies using an ELISA technique in a series of 105 skin carcinoma patients in comparison with a sex- and age-matched control skin carcinoma-free group (n = 130). Additionally, p53 accumulation was studied by immunohistochemistry to confirm p53 protein altered expression in a sample of tumours. Anti-p53 antibodies were detected in 2.9% of the cases, with a higher prevalence in patients suffering from the more aggressive squamous cell type (SCC) of skin carcinoma (8%) than for the more common and slowly growing basal cell carcinoma type or BCC (1.5%). p53 protein stabilization could be confirmed in 80% of tumours studied by IHC. This low level of anti-p53 antibody detection contrasts with the high rate of p53 mutations reported in these tumours. This observation shows that the anti-p53 humoral response is a complex and tissue-specific mechanism.
Moch
C
C
Unité INSERM U532, Institut de Recherche sur la Peau, Hôpital Saint-Louis, Paris, France.
Moysan
A
A
Lubin
R
R
de la Salmonière
P
P
Soufir
N
N
Galisson
F
F
Vilmer
C
C
Venutolo
E
E
Le Pelletier
F
F
Janin
A
A
Basset-Séguin
N
N
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000918:Antibody Specificity; D001323:Autoantibodies / Q000097:blood* / Q000276:immunology; D014408:Biomarkers, Tumor / Q000032:analysis; D002280:Basal Cell Carcinoma / Q000097:blood / Q000235:genetics* / Q000276:immunology / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000097:blood / Q000235:genetics* / Q000276:immunology / Q000473:pathology; D016022:Case-Control Studies; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D016158:Genes, p53; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000209:etiology; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000276:immunology*; D009381:Neoplasms, Radiation-Induced / Q000097:blood / Q000235:genetics / Q000276:immunology / Q000473:pathology; D011446:Prospective Studies; D012871:Skin Diseases / Q000097:blood / Q000235:genetics / Q000276:immunology / Q000473:pathology; D012878:Skin Neoplasms / Q000097:blood / Q000235:genetics* / Q000276:immunology / Q000473:pathology; D016159:Tumor Suppressor Protein p53 / Q000276:immunology*; D014466:Ultraviolet Rays / Q000009:adverse effects
D001323:Autoantibodies; D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; D016159:Tumor Suppressor Protein p53